The global injection pen market size was estimated at USD 40.0 billion in 2024 and is projected to reach USD 60.7 billion by 2030, growing at a CAGR of 7.4% from 2025 to 2030. The rising prevalence of chronic diseases such as osteoporosis, diabetes, cardiovascular diseases, and multiple sclerosis is a major driving force behind the increasing demand for injection pens.

Injection pens are particularly well-suited for managing chronic conditions that require frequent dosing, offering patients a convenient and effective way to administer medication regularly. A key factor contributing to market growth is the increasing adoption of innovative reusable injection pens, which provide environmental and economic benefits. Additionally, there is a growing demand for automated injection pens, which are favored by healthcare professionals due to their enhanced safety features, user-friendly design, convenience, and improved accuracy in delivering precise medication doses.

The surge in the number of diabetic patients worldwide and the serious health implications of the disease have further intensified the demand for insulin injection pens. According to data from the Institute for Health Metrics and Evaluation, over 500 million people globally are currently living with diabetes, affecting individuals of all ages and genders across every country. This figure is projected to exceed 1.3 billion within the next three decades, positioning diabetes as one of the leading causes of death and disability worldwide, with a current global prevalence rate of 6.1%. Furthermore, the National Institutes of Health (NIH) reports that sales of injection pens for insulin administration, particularly for treating type 2 diabetes, have surpassed those of traditional vial-based insulin delivery.

Injection pens have become the preferred method for self-administering insulin, largely because they offer greater ease of use compared to syringes used with vials. Patients find injection pens simpler and more convenient, which enhances adherence to treatment regimens and improves overall management of the disease. Consequently, the growing incidence of diabetes among the global population is directly contributing to the increased adoption and sales of injection pens in the market.

Key Market Trends & Insights:

• In 2024, North America held a dominant position in the global injection pen market, capturing a significant share of 44.7%. This strong foothold highlights the region's advanced healthcare infrastructure, widespread awareness of chronic disease management, and high adoption of innovative drug delivery technologies. Within the North American market, the United States led the way in 2023, serving as the largest and most influential market in the region for injection pens. This leadership is driven by factors such as extensive healthcare spending, a growing diabetic population, and ongoing technological advancements in injection devices.

• When examining the market by product type, the reusable injection pen segment accounted for the largest revenue share in 2024, representing 70.4% of the market. The preference for reusable pens is attributed to their cost-effectiveness, sustainability benefits, and convenience for patients who require frequent medication administration over extended periods. These features make reusable pens a popular choice among both healthcare providers and patients.

• By application, the diabetes segment emerged as the dominant category in 2024, holding a substantial share of 45.7%. This dominance reflects the widespread prevalence of diabetes and the critical need for efficient and user-friendly insulin delivery methods. Injection pens designed specifically for diabetes management have become essential tools in helping patients maintain better glycemic control and improve their quality of life.

• In terms of end-use settings, hospitals were the leading segment in 2024, accounting for the largest revenue share of 39.4%. Hospitals remain key centers for the administration of injection pens due to their role in acute care, patient education, and disease management. The substantial hospital share underscores the importance of these healthcare facilities in driving the demand for injection pens, particularly for patients requiring regular monitoring and treatment.

Order a free sample PDF of the Injection Pen Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 40.0 Billion

• 2030 Projected Market Size: USD 60.7 Billion

• CAGR (2025-2030): 7.4%

• North America: Largest market in 2024

• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights:

The injection pen industry is characterized by intense competition, with several leading players vying for strong market positions. Prominent companies such as BD (Becton, Dickinson and Company), Biocon, and Sanofi hold substantial shares and influence within the market. These key players are actively engaged in a variety of strategic initiatives aimed at maintaining and expanding their market presence.

To address the evolving needs of their customers and stay ahead in this competitive landscape, these major companies are pursuing both organic and inorganic growth strategies. Organic strategies include the continuous development and launch of innovative new products that offer improved functionality, ease of use, and patient compliance. Meanwhile, inorganic strategies involve forming collaborations and partnerships with other firms, as well as engaging in mergers and acquisitions to enhance their product portfolios and geographic reach.

Additionally, regional expansion efforts are a significant focus, as companies seek to enter new markets and increase their footprint in emerging regions where demand for injection pens is growing rapidly. Through these comprehensive approaches, leading industry players aim to better serve unmet customer needs, foster innovation, and secure a competitive edge in the global injection pen market.

Key Players

• BD

• Eli Lilly and Company

• Ypsomed AG

• Biocon

• Pfizer Inc.

• Novartis AG

• Novo Nordisk A/S

• Sanofi

• Owen Mumford Ltd.

• Merck KGaA

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The global injection pen market is experiencing significant growth, driven by the increasing prevalence of chronic diseases such as diabetes, osteoporosis, and anaphylaxis. The market is characterized by a shift towards reusable devices, which offer environmental benefits and cost-effectiveness. North America currently holds the largest market share, with the United States leading the region. Hospitals remain the primary end-use setting, although clinics are expected to see the fastest growth due to rising chronic disease cases and enhanced patient monitoring. Technological advancements continue to improve the functionality and user-friendliness of injection pens, further propelling market expansion.